15-Lipoxygenase-2 is differentially expressed in normal and neoplastic ovary

European Journal of Cancer Prevention

Volumn 16, Issue 6, 2007, Pages 568-575

  Roffeis, Jana ^a   Hornung, Daniela ^b   Kuhn, Hartmut ^a   Walther, Matthias ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Carcinogenesis; Eicosanoids; Expression regulation; Real time polymerase chain reaction

Indexed keywords

ARACHIDONATE 15 LIPOXYGENASE; ARACHIDONATE 15 LIPOXYGENASE 1; ARACHIDONATE 15 LIPOXYGENASE 2; ARACHIDONATE 5 LIPOXYGENASE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; MESSENGER RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; CYSTADENOCARCINOMA; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; METASTASIS; OVARY ADENOCARCINOMA; OVARY CARCINOMA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; STEADY STATE; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; ARACHIDONATE 15-LIPOXYGENASE; CA-125 ANTIGEN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYSTADENOCARCINOMA; EICOSANOIDS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; OVARY; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 37349077187     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e32801023c4     Document Type: Article

References (40)

1. Adib TR, Henderson S, Perrett C, Hewitt D, Bourmpoulia D, Ledermann J, Boshoff C (2004). Predicting biomarkers for ovarian cancer using geneexpression microarrays. Br J Cancer 90:686-692.
2. Akahira J, Sugihashi Y, Suzuki T, Ito K, Niikura H, Moriya T, et al. (2004). Decreased expression of 14-3-3 sigma is associated with advanced disease in human epithelial ovarian cancer: its correlation with aberrant DNA methylation. Clin Cancer Res 10:2687-2693.
3. Ali-Fehmi R, Che M, Khalifeh I, Malone JM, Morris R, Lawrence WD, Munkarah AR (2003). The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma. Cancer 98:1423-1429.
4. Auersperg N,Wong AS, Choi KC, Kang SK, Leung PC (2001). Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 22:255-288.
5. Balkwill F, Bast RC, Berek J, Chenevix-Trench G, Gore M, Hamilton T, et al. (2003). Current research and treatment for epithelial ovarian cancer. A position paper from the Helene Harris Memorial Trust. Eur J Cancer 39:1818-1827.
6. Berek JS, Bertelsen K, du Bois A, Brady MF, Carmichael J, Eisenhauer EA, et al. (2000). Epithelial ovarian cancer (advanced stage): consensus conference (1998). Gynecol Obstet Fertil 28:576-583.
7. Bhatia B, Maldonado CJ, Tang S, Chandra D, Klein RD, Chopra D, et al. (2003). Subcellular localization and tumor-suppressive functions of 15-lipoxygenase 2 (15-LOX2) and its splice variants. J Biol Chem 278:25091-25100.
8. Brash AR (1999). Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate. J Biol Chem 274:23679-23682.
9. Brash AR, Boeglin WE, Chang MS (1997). Discovery of a second 15S-lipoxygenase in humans. Proc Natl Acad Sci U S A 94:6148-6152.
10. Catalano A, Procopio A (2005). New aspects on the role of lipoxygenases in cancer progression. Histol Histopathol 20:969-975.
11. Cuendet M, Pezzuto JM (2000). The role of cyclooxygenase and lipoxygenase in cancer chemoprevention. Drug Metab Drug Interact 17:109-157.
12. Daikoku T, Wang D, Tranguch S, Morrow JD, Orsulic S, DuBois RN, Dey SK (2005). Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. Cancer Res 65:3735-3744.
13. DuBois RN (2003). Leukotriene A4 signaling, inflammation, and cancer. J Natl Cancer Inst 95:1028-1029.
14. Funk CD (2001). Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294:1871-1875.
15. Hanke JH,Webster KR, Ronco LV (2004). Protein biomarkers and drug design for cancer treatments. Eur J Cancer Prev 13:297-305.
16. Hsi LC,Wilson LC, Eling TE (2002). Opposing effects of 15-lipoxygenase-1 and -2 metabolites on MAPK signaling in prostate. Alteration in peroxisome proliferator-activated receptor gamma. J Biol Chem 277:40549- 40556.
17. Hubbard NE, Lim D, Erickson KL (1998). Alteration of murine mammary tumorigenesis by dietary enrichment with n-3 fatty acids in fish oil. Cancer Lett 124:1-7.
18. Jacobs IJ, Menon U (2004). Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 3:355-366.
19. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. (2005). Cancer statistics, 2005. CA Cancer J Clin 55:10-30.
20. Kelavkar UP, Nixon JB, Cohen C, Dillehay D, Eling TE, Badr KF (2001). Overexpression of 15-lipoxygenase-1 in PC-3 human prostate cancer cells increases tumorigenesis. Carcinogenesis 22:1765-1773.
21. Kelavkar U, Cohen C, Eling T, Badr K (2002). 15-Lipoxygenase-1 overexpression in prostate adenocarcinoma. Adv Exp Med Biol 507:133-145.
22. Li S, Miner K, Fannin R, Carl Barrett J, Davis BJ (2004). Cyclooxygenase-1 and 2 in normal and malignant human ovarian epithelium. Gynecol Oncol 92:622-627.
23. Mazhar D, Gillmore R, Waxman J (2005). COX and cancer. Q J Med 98: 711-718.
24. Meinhold-Heerlein I, Bauerschlag D, Hilpert F, Dimitrov P, Sapinoso LM, Orlowska-Volk M, et al. (2005). Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene 24:1053-1065.
25. Nasi ML, Castiglione M (2002). Cyclooxygenase-2 (COX-2) a new prognostic and predictive factor for ovarian cancer? Are all the criteria fulfilled? Ann Oncol 13:1169-1171.
26. Nie D, Hillman GG, Geddes T, Tang K, Pierson C, Grignon DJ, Honn KV (1998). Platelet-type 12-lipoxygenase in a human prostate carcinoma stimulates angiogenesis and tumor growth. Cancer Res 58:4047-4051.
27. Nixon JB, Kim KS, Lamb PW, Bottone FG, Eling TE (2004). 15-Lipoxygenase-1 has anti-tumorigenic effects in colorectal cancer. Prostaglandins Leukotrienes Essent Fatty Acids 70:7-15.
28. Roncella S, Ferro P, Bacigalupo B, Pronzato P, Tognoni A, Falco E, et al. (2005). Human mammaglobin mRNA is a reliable molecular marker for detecting occult breast cancer cells in peripheral blood. J Exp Clin Cancer Res 24:265-271.
29. Saito T, Kobayashi M, Harada R, Uemura Y, Taguchi H (2003). Sensitive detection of small cell lung carcinoma cells by reverse transcriptase-polymerase chain reaction for prepro-gastrin-releasing peptide mRNA. Cancer 97:2504-2511.
30. Samuelsson B, Dahlen SE, Lindgren JA, Rouzer CA, Serhan CN (1987). Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 237:1171-1176.
31. Schewe T, Halangk W, Hiebsch C, Rapoport SM (1975). A lipoxygenase in rabbit reticulocytes which attacks phospholipids and intact mitochondria. FEBS Lett 60:149-152.
32. Shappell SB, Boeglin WE, Olson SJ, Kasper S, Brash AR (1999). 15-Lipoxygenase-2 (15-LOX-2) is expressed in benign prostatic epithelium and reduced in prostate adenocarcinoma. Am J Pathol 155:235-245.
33. Shureiqi I, Jiang W, Zuo X, Wu Y, Stimmel JB, Leesnitzer LM, et al. (2003). The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-delta to induce apoptosis in colorectal cancer cells. Proc Natl Acad Sci U S A 100:9968-9973.
34. Simopoulos AP (2004). The traditional diet of Greece and cancer. Eur J Cancer Prev 13:219-230.
35. Skates SJ, Singer DE (1991). Quantifying the potential benefit of CA 125 screening for ovarian cancer. J Clin Epidemiol 44:365-380.
36. Smith WL, DeWitt DL, Garavito RM (2000). Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69:145-182.
37. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al. (2000). The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946-1952.
38. Tanimoto H, Yan Y, Clarke J, Korourian S, Shigemasa K, Parmley TH, et al. (1997). Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer. Cancer Res 57:2884-2887.
39. Wenham RM, Lancaster JM, Berchuck A (2002). Molecular aspects of ovarian cancer. Best Pract Res Clin Obstet Gynaecol 16:483-497.
40. Xu XC, Shappell SB, Liang Z, Song S, Menter D, Subbarayan V, et al. (2003). Reduced 15S-lipoxygenase-2 expression in esophageal cancer specimens and cells and upregulation in vitro by the cyclooxygenase-2 inhibitor, NS398. Neoplasia 5:121-127.